Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: Evolution of a dogma

Journal of Investigative Dermatology

Volumn 131, Issue 10, 2011, Pages 1968-1970

  Dutz, Jan ^a   Werth, Victoria P ^b,c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Perelman Center for Advanced Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CYTOCHROME P450 3A4; HYDROXYCHLOROQUINE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

CIGARETTE SMOKING; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HUMAN; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN LUPUS ERYTHEMATOSUS; STEADY STATE; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 80052856891     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.237     Document Type: Note

References (24)

1. Albrecht J, Werth VP (2010) Clinical outcome measures for cutaneous lupus erythematosus. Lupus 19:1137-43
2. Albrecht J, Taylor L, Berlin JA et al. (2005) The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889-94
3. Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150-4
4. Carmichael SJ, Charles B, Tett SE (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25:671-81 (Pubitemid 37499301)
5. Costedoat-Chalumeau N, Amoura Z et al. (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54:3284-90 (Pubitemid 44622099)
6. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al. (2007) Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 66:821-4 (Pubitemid 46846706)
7. Finlay AY (1996) Measure of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 7:149
8. Gallego H, Crutchfield CE 3rd, Lewis EJ et al. (1999) Report of an association between discoid lupus erythematosus and smoking. Cutis 63:231-4
9. Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983-7 (Pubitemid 30368665)
10. Klein RS, Morganroth PA, Werth VP (2010) Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. Rheum Dis Clin North Am 36:33-51, vii
11. Klein RS, Moghadam-Kia S, Lomonico J et al. (2011) Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 147:203-8
12. Koskenmies S, Jarvinen TM, Onkamo P et al. (2008) Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus 17:337-47 (Pubitemid 351655803)
13. Kuhn A, Kuehn E, Meuth AM et al. (2009) Development of a core set questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 8:702-12
14. Lardet D, Martin S, Truchetet F et al. (2004) [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study]. Rev Med Interne 25:786-91 (Pubitemid 40292251)
15. Leroux G, Costedoat-Chalumeau N, Hulot JS et al. (2007) Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann Rheum Dis 66:1547-8 (Pubitemid 350032673)
16. Lopez P, Gomez J, Mozo L et al. (2006) Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res Ther 8:R42
17. Moghadam-Kia S, Chilek K, Gaines E et al. (2009) Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 145:255-60
18. Piette EW, Foering KP, Chang AY et al. (2011) The effect of smoking in cutaneous lupus erythematosus and dermatomyositis. J Invest Dermatol 131:S86
19. Rahman P, Gladman DD, Urowitz MB (1998) Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 25:1716-9 (Pubitemid 28439264)
20. Tett SE, Day RO, Cutler DJ (1993) Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis-a cross sectional study. J Rheumatol 20:1874-9 (Pubitemid 24031590)
21. Turchin I, Bernatsky S, Clarke AE et al. (2009) Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol 36:2691-3
22. Wahie S, McColl E, Reynolds NJ et al. (2010) Measuring disease activity and damage in discoid lupus erythematosus. Br J Dermatol 162:1030-7
23. Wahie S, Daly AK, Cordell HJ (2011) Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol 131:1981-6
24. Yang W, Zilov A, Soewondo P et al. (2010) Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res Clin Pract 88(Suppl 1):S3-9